NCT01088815 - Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 17, 2010

Primary Completion Date

December 1, 2017

Study Completion Date

February 17, 2018

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG

Gemcitabine, nab-Paclitaxel, GDC-0449

"1. One cycle of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 (28 days cycle) then~2. Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days cycle in combination with oral GDC-0449 150 mg daily"

Trial Locations (3)

19104

University of Pennsylvania, Philadelphia

21205

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

85258

Translational Genomics Research Institute (TGen), Scottsdale